3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
205
Carcinoma, Non-Small-Cell Lung
130
Neoplasms
101
Neoplasm Metastasis
70
Breast Neoplasms
66
Ovarian Neoplasms
42
Urinary Bladder Neoplasms
37
Lung Neoplasms
37
Triple Negative Breast Neoplasms
34
Colorectal Neoplasms
30
Lymphoma, Large B-Cell, Diffuse
29
Cholangiocarcinoma
28
Biliary Tract Neoplasms
27
Carcinoma, Transitional Cell
23
Lymphoma, Non-Hodgkin
22
Adenocarcinoma
22
Recurrence
21
Lymphoma
20
Fallopian Tube Neoplasms
18
Stomach Neoplasms
15
Sarcoma
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Non-Muscle Invasive Bladder Neoplasms
13
Carcinoma, Pancreatic Ductal
13
Nasopharyngeal Carcinoma
12
Gallbladder Neoplasms
12
Bile Duct Neoplasms
11
Melanoma
10
Carcinoma
10
Solid Tumors
9
Interventions
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metatropic dwarfism
×
Gemcitabine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts